Robert Davis - CR Bard Director

Director

Mr. Robert M. Davis is an Independent Director of the Company. He is Executive Vice President and Chief Financial Officer of Merck Co., Inc. since April 2014. Prior to that, Mr. Davis served as Corporationrationrate Vice President and President of Baxter Renal Division from June 2010 to October 2010 and Corporationrationrate Vice President and President of Baxter Medical Products from October 2010 to April 2014, having been Corporationrationrate Vice President and Chief Financial Officer of Baxter Healthcare from May 2006 to June 2010, and Treasurer of Baxter Healthcare from November 2004 to May 2006. He also served as Director of Corporationrationrate Financial Planning of Eli Lilly and Company from 2002 to 2004, and as Assistant Treasurer and various financial positions at Eli Lilly and Company from 1990 to 2002 since 2016.
Age 49
Tenure 8 years
Professional MarksMBA
Phone908 277-8000
Webwww.crbard.com
Davis was nominated to serve as a director as a result of, among other things, his significant experience in management, strategy, business development, finance, accounting for public companies and technical operations for global companies. This experience includes his service as the Chief Financial Officer of Merck, as well as his prior experience gained in a variety of management and finance roles at Baxter International. He holds both a B.S. in business from Miami University in Ohio, as well as an M.B.A. and a J.D. from Northwestern University in Chicago.

CR Bard Management Efficiency

CR Bard's management efficiency ratios could be used to measure how well CR Bard manages its routine affairs as well as how well it operates its assets and liabilities.
The company has 1.64 B in debt with debt to equity (D/E) ratio of 81.4, demonstrating that the company may be unable to create cash to meet all of its financial commitments. CR Bard has a current ratio of 1.69, which is typical for the industry and considered as normal. Debt can assist CR Bard until it has trouble settling it off, either with new capital or with free cash flow. So, CR Bard's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like CR Bard sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for BCR to invest in growth at high rates of return. When we think about CR Bard's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Heather CianfroccoNational Vision Holdings
45
Malcolm WallNational Vision Holdings
57
Richard BeyerKNOT Offshore Partners
50
Douglas HultquistUnited Fire Group
58
Brian HoestereyGMS Inc
51
Joel AlsfineAsbury Automotive Group
51
Thomas TaylorNational Vision Holdings
52
Eugene KatzAsbury Automotive Group
73
Yutaka HigurashiKNOT Offshore Partners
50
David SmithGMS Inc
68
Hans AasKNOT Offshore Partners
74
Steven KornBrp Group
63
W CappsBrp Group
66
Patricia McGinnisBrp Group
69
Robert LoudermilkGenuine Parts Co
61
Peter BrowningGMS Inc
79
JohnPaul BesongUnited Fire Group
64
Yoshiyuki KonumaKNOT Offshore Partners
52
Scott CarltonUnited Fire Group
49
Bridget RyanBermanAsbury Automotive Group
60
Edward WaryasKNOT Offshore Partners
72
C. R. Bard, Inc., together with its subsidiaries, designs, manufactures, packages, distributes, and sells medical, surgical, diagnostic, and patient care devices worldwide. CR Bard (BCR) is traded on New York Stock Exchange in USA and employs 14,900 people.

Management Performance

CR Bard Leadership Team

Elected by the shareholders, the CR Bard's board of directors comprises two types of representatives: CR Bard inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BCR. The board's role is to monitor CR Bard's management team and ensure that shareholders' interests are well served. CR Bard's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CR Bard's outside directors are responsible for providing unbiased perspectives on the board's policies.
James Beasley, Group President
Patricia Christian, Vice President - Quality, Regulatory and Medical Affairs
Sharon Alterio, Group Vice President
Todd Garner, Vice President - Investor Relations
Marc Breslawsky, Independent Director
John Weiland, President, COO and Director
John DeFord, Senior Vice President - Science, Technology and Clinical Affairs
Frank Lupisella, Principal Accounting Officer, VP and Controller
Betty Larson, Vice President Human Resources.
John Groetelaars, Group Vice President
Tony White, Independent Director
Gerard Porreca, Vice President - Quality, Regulatory and Medical Affairs
Robert Davis, Director
Anthony Welters, Independent Director
Gail Naughton, Independent Director
John Kelly, Independent Director
Tommy Thompson, Independent Director
Samrat Khichi, Senior Vice President General Counsel, Secretary
Sharon Luboff, Group Vice President
Herbert Henkel, Lead Independent Director
Christopher Holland, CFO and Sr. VP
David Melcher, Director
Jim Beasley, Group Pres
Timothy Collins, Group Pres
Timothy Ring, Chairman, CEO and Chairman of Executive Committee
David Barrett, Independent Director

BCR Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is CR Bard a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards CR Bard in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, CR Bard's short interest history, or implied volatility extrapolated from CR Bard options trading.

Pair Trading with CR Bard

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CR Bard position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CR Bard will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Sunoco LP could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sunoco LP when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sunoco LP - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sunoco LP to buy it.
The correlation of Sunoco LP is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sunoco LP moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sunoco LP moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sunoco LP can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.
Note that the CR Bard information on this page should be used as a complementary analysis to other CR Bard's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the CEOs Directory module to screen CEOs from public companies around the world.

Other Consideration for investing in BCR Stock

If you are still planning to invest in CR Bard check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the CR Bard's history and understand the potential risks before investing.
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Stocks Directory
Find actively traded stocks across global markets